TVTX vs. CPRX, LGND, BMEA, IDYA, CRNX, CTIC, ETNB, PLRX, MNKD, and ARVN
Should you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Catalyst Pharmaceuticals (CPRX), Ligand Pharmaceuticals (LGND), Biomea Fusion (BMEA), IDEAYA Biosciences (IDYA), Crinetics Pharmaceuticals (CRNX), CTI BioPharma (CTIC), 89bio (ETNB), Pliant Therapeutics (PLRX), MannKind (MNKD), and Arvinas (ARVN). These companies are all part of the "pharmaceutical preparations" industry.
Travere Therapeutics vs.
Catalyst Pharmaceuticals (NASDAQ:CPRX) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, community ranking, institutional ownership, valuation, risk, analyst recommendations and earnings.
In the previous week, Catalyst Pharmaceuticals had 4 more articles in the media than Travere Therapeutics. MarketBeat recorded 17 mentions for Catalyst Pharmaceuticals and 13 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 0.34 beat Catalyst Pharmaceuticals' score of 0.18 indicating that Travere Therapeutics is being referred to more favorably in the news media.
Catalyst Pharmaceuticals currently has a consensus price target of $21.50, indicating a potential upside of 86.31%. Travere Therapeutics has a consensus price target of $30.85, indicating a potential upside of 63.99%. Given Catalyst Pharmaceuticals' higher probable upside, equities analysts clearly believe Catalyst Pharmaceuticals is more favorable than Travere Therapeutics.
Catalyst Pharmaceuticals has higher revenue and earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Catalyst Pharmaceuticals has a net margin of 38.76% compared to Travere Therapeutics' net margin of -130.98%. Catalyst Pharmaceuticals' return on equity of 34.72% beat Travere Therapeutics' return on equity.
86.7% of Catalyst Pharmaceuticals shares are owned by institutional investors. 14.1% of Catalyst Pharmaceuticals shares are owned by insiders. Comparatively, 4.7% of Travere Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Catalyst Pharmaceuticals received 431 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 74.88% of users gave Catalyst Pharmaceuticals an outperform vote while only 46.25% of users gave Travere Therapeutics an outperform vote.
Catalyst Pharmaceuticals has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.
Summary
Catalyst Pharmaceuticals beats Travere Therapeutics on 14 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Travere Therapeutics Competitors List
Related Companies and Tools
